Tempest Therapeutics received ‘Study May Proceed’ letter from FDA on TPST-1495
Tempest Therapeutics (TPST) announced that the Cancer Prevention Clinical Trials Network received a “Study May Proceed” letter from the U.S.
FDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP)
Second clinical program entering Phase 2 with data expected 2026BRISBANE, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Tempest ...
Nasdaq6d
Tempest Therapeutics Receives FDA Clearance For Phase 2 Trial Of TPST-1495 In FAP
a novel dual receptor inhibitor of prostaglandin or PGE2 signaling, for the treatment of Familial Adenomatous Polyposis or FAP. The clearance follows the successful submission of the IND ...
Morningstar6d
FDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP)
the company’s novel dual receptor inhibitor of prostaglandin (PGE2) signaling, in a Phase 2 clinical trial for the treatment of patients with Familial Adenomatous Polyposis (FAP). “Receiving ...
The Hamilton Spectator5d
King Charles signalling support for Canada as Trump talks annexation: royal watchers
A maple tree, a red dress and a ceremonial sword may seem like cold comfort for Canadians hoping to hear their head of state defend them against U.S. President Donald Trump’s repeated pitches to ...
SignalSCV1d
The Santa Clarita Valley Signal | #1 source for breaking and local news
Filled with the top stories to start your day, and emergency news alerts.
Frontiers6d
Frontiers in Signal Processing
Impact and progress Frontiers' impact Progress Report 2022 All annual reports ...